AXS Investments LLC Cuts Stake in Eli Lilly and Company (NYSE:LLY)

AXS Investments LLC lessened its holdings in Eli Lilly and Company (NYSE:LLY) by 5.0% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 2,475 shares of the company’s stock after selling 129 shares during the period. AXS Investments LLC’s holdings in Eli Lilly and Company were worth $1,443,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of LLY. Lipe & Dalton acquired a new stake in Eli Lilly and Company in the 4th quarter valued at about $26,000. Tidemark LLC purchased a new position in Eli Lilly and Company in the fourth quarter worth approximately $29,000. Optiver Holding B.V. purchased a new position in Eli Lilly and Company in the third quarter worth approximately $36,000. St. Johns Investment Management Company LLC grew its holdings in Eli Lilly and Company by 123.3% during the 4th quarter. St. Johns Investment Management Company LLC now owns 67 shares of the company’s stock worth $39,000 after acquiring an additional 37 shares in the last quarter. Finally, O Brien Wealth Partners LLC increased its position in shares of Eli Lilly and Company by 70.5% in the 4th quarter. O Brien Wealth Partners LLC now owns 75 shares of the company’s stock valued at $44,000 after purchasing an additional 31 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Price Performance

Shares of Eli Lilly and Company stock traded up $0.66 during trading on Friday, reaching $809.11. The company’s stock had a trading volume of 1,025,195 shares, compared to its average volume of 2,985,917. The business has a 50 day moving average price of $764.43 and a 200-day moving average price of $690.85. Eli Lilly and Company has a 12-month low of $419.80 and a 12-month high of $820.60. The company has a market capitalization of $768.99 billion, a P/E ratio of 119.20, a price-to-earnings-growth ratio of 1.75 and a beta of 0.37. The company has a quick ratio of 1.03, a current ratio of 1.35 and a debt-to-equity ratio of 1.90.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Monday, May 6th. The company reported $2.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.53 by $0.05. The business had revenue of $8.77 billion during the quarter, compared to the consensus estimate of $8.94 billion. Eli Lilly and Company had a net margin of 17.08% and a return on equity of 56.98%. The business’s revenue was up 26.0% compared to the same quarter last year. During the same quarter last year, the firm posted $1.62 EPS. As a group, sell-side analysts anticipate that Eli Lilly and Company will post 13.78 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, June 10th. Shareholders of record on Thursday, May 16th will be given a dividend of $1.30 per share. The ex-dividend date is Wednesday, May 15th. This represents a $5.20 dividend on an annualized basis and a yield of 0.64%. Eli Lilly and Company’s payout ratio is 76.58%.

Wall Street Analyst Weigh In

Several equities analysts recently commented on LLY shares. Wells Fargo & Company increased their target price on Eli Lilly and Company from $700.00 to $825.00 and gave the company an “overweight” rating in a report on Tuesday, February 6th. BMO Capital Markets boosted their target price on Eli Lilly and Company from $900.00 to $1,001.00 and gave the stock an “outperform” rating in a research note on Wednesday, May 1st. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $885.00 price target (up from $815.00) on shares of Eli Lilly and Company in a report on Tuesday, April 30th. Truist Financial raised their price objective on shares of Eli Lilly and Company from $850.00 to $892.00 and gave the stock a “buy” rating in a report on Wednesday, May 1st. Finally, Citigroup upped their target price on shares of Eli Lilly and Company from $675.00 to $895.00 and gave the company a “buy” rating in a report on Tuesday, April 2nd. Three investment analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $769.53.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.